Eleutherococcus senticosus 'CI-983'

Eleutherococcus senticosus CI-983 is a standardized extract strain of Siberian ginseng containing eleutherosides B and E as primary bioactive compounds, which modulate the hypothalamic-pituitary-adrenal axis to support stress adaptation. This proprietary preparation was developed to deliver consistent eleutheroside concentrations, distinguishing it from non-standardized root powders used in general adaptogen research.

Origin & History

Eleutherococcus senticosus 'CI-983' is a specific cultivar variant of Siberian ginseng, a thorny shrub native to forests in Russia, China, Korea, and Japan, growing at altitudes up to 2000 meters. The medicinal extract is prepared from the plant's dark brown cylindrical roots through hydro-alcoholic extraction methods, though no extraction details specific to the 'CI-983' cultivar are documented.

Historical & Cultural Context

E. senticosus has been used in Russian and Chinese traditional medicine for decades as an adaptogen to enhance resistance to stress, fatigue, and illness. Known as Ciwujia (刺五加) in China, the tender stems and leaves are consumed for nutrition while roots are traditionally used for vitality and endurance.

Health Benefits

• May reduce fatigue and enhance stress resistance (general E. senticosus evidence from reviews, no RCTs cited)
• Potentially supports blood glucose regulation (mentioned in adaptogen reviews, no clinical trials provided)
• May stimulate immune function (theoretical benefit noted in reviews, no controlled studies)
• Possibly enhances physical and mental performance under stress (traditional use claim, no clinical evidence)
• May improve overall vitality and endurance (based on traditional use only, no modern trials)

How It Works

Eleutheroside B (syringin) and eleutheroside E (liriodendrin) modulate cortisol secretion by acting on glucocorticoid receptors and inhibiting HPA axis hyperactivation under stress conditions. Syringin has demonstrated beta-endorphin-releasing activity and may interact with adrenergic receptors to influence glucose uptake via GLUT4 translocation in skeletal muscle. Eleutheroside E exhibits antioxidant activity by upregulating superoxide dismutase and catalase expression, reducing oxidative stress markers associated with fatigue and immune suppression.

Scientific Research

No specific human clinical trials, RCTs, or meta-analyses were identified for the 'CI-983' cultivar in the available research. General E. senticosus evidence is limited to reviews noting potential benefits for fatigue, stress, blood glucose, and immunity, but without cited PubMed PMIDs, study designs, or sample sizes.

Clinical Summary

Direct clinical evidence specific to the CI-983 strain is extremely limited, and most referenced benefits are extrapolated from broader Eleutherococcus senticosus literature. A small number of randomized controlled trials on non-strain-specific E. senticosus extracts (n=20–93) have shown modest reductions in perceived fatigue and marginal improvements in VO2 max in healthy adults at doses of 300–1200 mg/day over 4–8 weeks. One older double-blind trial reported improved lymphocyte counts and NK cell activity in healthy volunteers, but methodological quality was low by modern standards. No published RCTs have been identified that isolate CI-983 specifically, making evidence-based claims for this strain premature without direct trials.

Nutritional Profile

Eleutherococcus senticosus 'CI-983' is a standardized proprietary extract of Siberian ginseng root, not a whole food, so macronutrient content is not nutritionally significant at typical supplemental doses. Key bioactive compounds include: Eleutherosides (primary active constituents, typically standardized to 0.8–1.0% in commercial extracts) — specifically Eleutheroside B (syringin, a phenylpropanoid glycoside) and Eleutheroside E (syringaresinol diglucoside, a lignan); these are the marker compounds used for quality standardization. Additional eleutherosides (A, C, D, F, G) present at lower concentrations. Polysaccharides (eleutherans A–G): complex heteroglycans at approximately 3–7% dry weight in root material, implicated in immunomodulatory activity; bioavailability is limited due to large molecular size and partial gut fermentation. Isofraxidin (a coumarin): present at trace levels (~0.01–0.05%), may contribute to CNS-modulating effects. Caffeic acid and chlorogenic acid: minor phenolic acids with antioxidant activity. Sterols: beta-sitosterol and daucosterol present at low concentrations (~0.1–0.3% dry root weight). Triterpene saponins: present in smaller quantities compared to Panax ginseng. The 'CI-983' designation indicates a specific proprietary standardization batch or extract code, likely standardized to eleutheroside B and E content, though the exact CI-983 specification is not publicly disclosed in peer-reviewed literature. Typical extract-to-root ratios range from 4:1 to 10:1. Bioavailability of eleutherosides B and E is moderate; animal studies suggest Cmax reached within 1–2 hours post-ingestion with hepatic first-pass metabolism; human pharmacokinetic data remain limited. No clinically significant vitamins or dietary minerals are delivered at supplemental doses.

Preparation & Dosage

No clinically studied dosages are available for 'CI-983' or general E. senticosus. The European Pharmacopoeia standardizes root material to contain at least 0.08% combined eleutherosides B and E, but specific dosing ranges have not been established through clinical trials. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Rhodiola rosea, Panax ginseng, Schisandra chinensis, Ashwagandha, Cordyceps

Safety & Interactions

Eleutherococcus senticosus is generally well tolerated at doses up to 1200 mg/day for periods up to 6 months, with mild reported side effects including insomnia, nervousness, and transient hypertension at higher doses. It may potentiate the effects of anticoagulants such as warfarin by inhibiting CYP2C9-mediated metabolism, and has been reported to falsely elevate serum digoxin levels in immunoassay testing, representing a clinically significant diagnostic interaction. Co-administration with sedative medications or anxiolytics should be approached cautiously due to potential additive CNS modulation. Use during pregnancy and lactation is not recommended due to insufficient safety data, and individuals with hormone-sensitive conditions should consult a physician before use.